Published in Cancer Microenviron on July 26, 2012
c-Myc is essential to prevent endothelial pro-inflammatory senescent phenotype. PLoS One (2013) 0.82
Functional genetic variants of TNFSF15 and their association with gastric adenocarcinoma: a case-control study. PLoS One (2014) 0.78
The Impact of Serum Amyloid P-Component on Gene Expression in RAW264.7 Mouse Macrophages. Biomed Res Int (2016) 0.75
Transcriptome sequencing reveals that LPS-triggered transcriptional responses in established microglia BV2 cell lines are poorly representative of primary microglia. J Neuroinflammation (2016) 0.75
TNFSF15 Inhibits Blood Retinal Barrier Breakdown Induced by Diabetes. Int J Mol Sci (2016) 0.75
Dendritic cells and the control of immunity. Nature (1998) 56.54
Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science (1994) 12.83
Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol (2003) 10.29
Tumor necrosis factor signaling. Cell Death Differ (2003) 8.48
Signal transduction by tumor necrosis factor and its relatives. Trends Cell Biol (2001) 6.73
Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors. Nature (1986) 5.68
Elevated levels of circulating cachectin/tumor necrosis factor in patients with acquired immunodeficiency syndrome. Am J Med (1988) 4.67
Dendritic cell immunotherapy: mapping the way. Nat Med (2004) 4.28
Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-vs.-host disease. J Exp Med (1987) 3.62
TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator. Immunity (2002) 3.46
The molecular architecture of the TNF superfamily. Trends Biochem Sci (2002) 3.39
Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature (1998) 2.98
Signal transduction by DR3, a death domain-containing receptor related to TNFR-1 and CD95. Science (1996) 2.87
Interactions of tumor necrosis factor (TNF) and TNF receptor family members in the mouse and human. J Biol Chem (2006) 2.75
TL1A-DR3 interaction regulates Th17 cell function and Th17-mediated autoimmune disease. J Exp Med (2008) 2.33
Tumor necrosis factor is a critical mediator in hapten induced irritant and contact hypersensitivity reactions. J Exp Med (1991) 2.24
Regulation of proliferation, survival and apoptosis by members of the TNF superfamily. Biochem Pharmacol (2003) 2.22
Expression, localization, and functional activity of TL1A, a novel Th1-polarizing cytokine in inflammatory bowel disease. J Immunol (2003) 2.21
Interleukin-1 and tumour necrosis factor mRNA expression in rheumatoid arthritis: prolonged production of IL-1 alpha. Clin Exp Immunol (1988) 2.06
A death-domain-containing receptor that mediates apoptosis. Nature (1996) 1.92
Essential role of TNF receptor superfamily 25 (TNFRSF25) in the development of allergic lung inflammation. J Exp Med (2008) 1.89
Structure of the TRAIL-DR5 complex reveals mechanisms conferring specificity in apoptotic initiation. Nat Struct Biol (1999) 1.88
Targeting RGD recognizing integrins: drug development, biomaterial research, tumor imaging and targeting. Curr Pharm Des (2006) 1.88
Role of TL1A and its receptor DR3 in two models of chronic murine ileitis. Proc Natl Acad Sci U S A (2006) 1.87
TL1A synergizes with IL-12 and IL-18 to enhance IFN-gamma production in human T cells and NK cells. J Immunol (2004) 1.85
TRAMP, a novel apoptosis-mediating receptor with sequence homology to tumor necrosis factor receptor 1 and Fas(Apo-1/CD95). Immunity (1997) 1.74
Apo-3, a new member of the tumor necrosis factor receptor family, contains a death domain and activates apoptosis and NF-kappa B. Curr Biol (1996) 1.72
Overexpression of M68/DcR3 in human gastrointestinal tract tumors independent of gene amplification and its location in a four-gene cluster. Proc Natl Acad Sci U S A (2000) 1.67
The TNF-family cytokine TL1A drives IL-13-dependent small intestinal inflammation. Mucosal Immunol (2010) 1.65
Sustained TL1A expression modulates effector and regulatory T-cell responses and drives intestinal goblet cell hyperplasia. Mucosal Immunol (2010) 1.61
LARD: a new lymphoid-specific death domain containing receptor regulated by alternative pre-mRNA splicing. Proc Natl Acad Sci U S A (1997) 1.58
Soluble decoy receptor 3 is expressed by malignant gliomas and suppresses CD95 ligand-induced apoptosis and chemotaxis. Cancer Res (2001) 1.58
The T cell costimulator TL1A is induced by FcgammaR signaling in human monocytes and dendritic cells. J Immunol (2007) 1.56
Dominant role for TL1A/DR3 pathway in IL-12 plus IL-18-induced IFN-gamma production by peripheral blood and mucosal CCR9+ T lymphocytes. J Immunol (2005) 1.51
Soluble TNF-like cytokine (TL1A) production by immune complexes stimulated monocytes in rheumatoid arthritis. J Immunol (2007) 1.44
TL1A-induced NF-kappaB activation and c-IAP2 production prevent DR3-mediated apoptosis in TF-1 cells. J Biol Chem (2003) 1.40
Involvement of TL1A and DR3 in induction of pro-inflammatory cytokines and matrix metalloproteinase-9 in atherogenesis. Cytokine (2005) 1.40
The prognostic significance of overexpression of the decoy receptor for Fas ligand (DcR3) in patients with gastric carcinomas. Gastric Cancer (2002) 1.37
Synovial localization of tumor necrosis factor in patients with rheumatoid arthritis. J Autoimmun (1988) 1.33
VEGI, a novel cytokine of the tumor necrosis factor family, is an angiogenesis inhibitor that suppresses the growth of colon carcinomas in vivo. FASEB J (1999) 1.29
Genes encoding tumor necrosis factor alpha and granzyme A are expressed during development of autoimmune diabetes. Proc Natl Acad Sci U S A (1990) 1.28
Dendritic cells: immunobiology and cancer immunotherapy. Immunity (2004) 1.27
Neonatal and adult CD4+ CD3- cells share similar gene expression profile, and neonatal cells up-regulate OX40 ligand in response to TL1A (TNFSF15). J Immunol (2006) 1.26
Genetic predictors of medically refractory ulcerative colitis. Inflamm Bowel Dis (2010) 1.25
Modulation of endothelial cell growth arrest and apoptosis by vascular endothelial growth inhibitor. Circ Res (2001) 1.23
Tumor necrosis factor-alpha in human arterial wall with atherosclerosis. Atherosclerosis (1991) 1.21
Modulation of dendritic cell differentiation and maturation by decoy receptor 3. J Immunol (2002) 1.20
Microbial induction of inflammatory bowel disease associated gene TL1A (TNFSF15) in antigen presenting cells. Eur J Immunol (2009) 1.18
TL1A both promotes and protects from renal inflammation and injury. J Am Soc Nephrol (2008) 1.18
Modulation of T-cell responses to alloantigens by TR6/DcR3. J Clin Invest (2001) 1.16
Soluble decoy receptor 3 induces angiogenesis by neutralization of TL1A, a cytokine belonging to tumor necrosis factor superfamily and exhibiting angiostatic action. Cancer Res (2004) 1.14
Decoy receptor 3 expressed in rheumatoid synovial fibroblasts protects the cells against Fas-induced apoptosis. Arthritis Rheum (2007) 1.13
Inhibition of angiogenesis and breast cancer xenograft tumor growth by VEGI, a novel cytokine of the TNF superfamily. Int J Cancer (1999) 1.11
Evaluation of 22 genetic variants with Crohn's disease risk in the Ashkenazi Jewish population: a case-control study. BMC Med Genet (2011) 1.10
A novel secreted splice variant of vascular endothelial cell growth inhibitor. FASEB J (2002) 1.10
Constitutive TL1A (TNFSF15) expression on lymphoid or myeloid cells leads to mild intestinal inflammation and fibrosis. PLoS One (2011) 1.08
Decoy receptor 3 increases monocyte adhesion to endothelial cells via NF-kappa B-dependent up-regulation of intercellular adhesion molecule-1, VCAM-1, and IL-8 expression. J Immunol (2005) 1.05
Population-specific susceptibility to Crohn's disease and ulcerative colitis; dominant and recessive relative risks in the Japanese population. Ann Hum Genet (2010) 1.04
LITAF and TNFSF15, two downstream targets of AMPK, exert inhibitory effects on tumor growth. Oncogene (2011) 1.03
TL1A: a mediator of gut inflammation. Proc Natl Acad Sci U S A (2006) 1.02
Naive and activated T cells display differential responsiveness to TL1A that affects Th17 generation, maintenance, and proliferation. FASEB J (2010) 1.01
Investigation of multiple susceptibility loci for inflammatory bowel disease in an Italian cohort of patients. PLoS One (2011) 1.00
VEGI, a new member of the TNF family activates nuclear factor-kappa B and c-Jun N-terminal kinase and modulates cell growth. Oncogene (1999) 1.00
Inhibition of type 1 diabetes in BB rats with recombinant human tumor necrosis factor-alpha. J Immunol (1990) 0.98
Functional characterisation of decoy receptor 3 in Crohn's disease. Gut (2008) 0.98
Inhibition of endothelial progenitor cell differentiation by VEGI. Blood (2009) 0.97
Amplification and expression of a decoy receptor for fas ligand (DcR3) in virus (EBV or HTLV-I) associated lymphomas. Cancer Lett (2000) 0.95
High intestinal and systemic levels of decoy receptor 3 (DcR3) and its ligand TL1A in active ulcerative colitis. Clin Immunol (2010) 0.95
The endothelial cell-produced antiangiogenic cytokine vascular endothelial growth inhibitor induces dendritic cell maturation. J Immunol (2007) 0.94
The adaptor protein TRADD is essential for TNF-like ligand 1A/death receptor 3 signaling. J Immunol (2011) 0.94
VEGI-192, a new isoform of TNFSF15, specifically eliminates tumor vascular endothelial cells and suppresses tumor growth. Clin Cancer Res (2005) 0.94
DcR3 induces cell proliferation through MAPK signaling in chondrocytes of osteoarthritis. Osteoarthritis Cartilage (2011) 0.94
X-ray crystal structure of TNF ligand family member TL1A at 2.1A. Biochem Biophys Res Commun (2007) 0.93
Upregulation and nuclear localization of TNF-like cytokine 1A (TL1A) and its receptors DR3 and DcR3 in psoriatic skin lesions. Exp Dermatol (2011) 0.93
Biochemical and structural characterization of the human TL1A ectodomain. Biochemistry (2009) 0.92
Reduced vascular endothelial growth inhibitor (VEGI) expression is associated with poor prognosis in breast cancer patients. Angiogenesis (2006) 0.90
Effects of endostatin-vascular endothelial growth inhibitor chimeric recombinant adenoviruses on antiangiogenesis. World J Gastroenterol (2004) 0.90
Constitutive TL1A expression under colitogenic conditions modulates the severity and location of gut mucosal inflammation and induces fibrostenosis. Am J Pathol (2011) 0.90
Impaired production of tumor necrosis factor in breast cancer. Cancer (1990) 0.89
TL1A selectively enhances IL-12/IL-18-induced NK cell cytotoxicity against NK-resistant tumor targets. J Clin Immunol (2010) 0.88
The role of vascular endothelial growth inhibitor in wound healing. Int Wound J (2007) 0.88
Molecular cloning and functional characterizations of chicken TL1A. Dev Comp Immunol (2005) 0.87
Characterization of synovial angiogenesis in osteoarthritis patients and its modulation by chondroitin sulfate. Arthritis Res Ther (2012) 0.86
TLR8-mediated activation of human monocytes inhibits TL1A expression. Eur J Immunol (2009) 0.85
Expression of vascular endothelial growth inhibitor (VEGI) in human urothelial cancer of the bladder and its effects on the adhesion and migration of bladder cancer cells in vitro. Anticancer Res (2010) 0.85
DcR3-TL1A signalling inhibits cytokine-induced proliferation of rheumatoid synovial fibroblasts. Int J Mol Med (2011) 0.85
Down-modulation of TNFSF15 in ovarian cancer by VEGF and MCP-1 is a pre-requisite for tumor neovascularization. Angiogenesis (2011) 0.85
Vascular endothelial growth inhibitor (VEGI; TNFSF15) inhibits bone marrow-derived endothelial progenitor cell incorporation into Lewis lung carcinoma tumors. Angiogenesis (2010) 0.84
Immunomodulatory effect of decoy receptor 3 on the differentiation and function of bone marrow-derived dendritic cells in nonobese diabetic mice: from regulatory mechanism to clinical implication. J Leukoc Biol (2003) 0.84
Involvement of NF-kappa B pathway in TL1A gene expression induced by lipopolysaccharide. Cytokine (2009) 0.84
Decoy receptor 3 is highly expressed in patients with rheumatoid arthritis. Mod Rheumatol (2009) 0.84
Characterization of cis-regulatory elements of the vascular endothelial growth inhibitor gene promoter. Biochem J (2005) 0.84
Functional signaling of membrane-bound TL1A induces IFN-gamma expression. FEBS Lett (2010) 0.83
Dual function of RGD-modified VEGI-192 for breast cancer treatment. Bioconjug Chem (2012) 0.81
Approaches to efficient production of recombinant angiogenesis inhibitor rhVEGI-192 and characterization of its structure and antiangiogenic function. Protein Sci (2010) 0.81
Distinct immunoregulatory properties of macrophage migration inhibitory factors encoded by Eimeria parasites and their chicken host. Vaccine (2011) 0.81
Innate immunity: cells, receptors, and signaling pathways. Arch Immunol Ther Exp (Warsz) (2005) 0.81
CD161 DEFINES EFFECTOR T CELLS THAT EXPRESS LIGHT AND RESPOND TO TL1A-DR3 SIGNALING. Eur J Microbiol Immunol (Bp) (2011) 0.81
Human rhomboid family-1 gene RHBDF1 participates in GPCR-mediated transactivation of EGFR growth signals in head and neck squamous cancer cells. FASEB J (2008) 1.21
Human rhomboid family-1 gene silencing causes apoptosis or autophagy to epithelial cancer cells and inhibits xenograft tumor growth. Mol Cancer Ther (2008) 1.12
Guaianolide sesquiterpene lactones, a source to discover agents that selectively inhibit acute myelogenous leukemia stem and progenitor cells. J Med Chem (2012) 1.11
A novel secreted splice variant of vascular endothelial cell growth inhibitor. FASEB J (2002) 1.10
SOX2 regulates apoptosis through MAP4K4-survivin signaling pathway in human lung cancer cells. Carcinogenesis (2013) 1.05
Direct chemotactic action of angiopoietin-1 on mesenchymal cells in the presence of VEGF. Microvasc Res (2004) 0.97
Inhibition of endothelial progenitor cell differentiation by VEGI. Blood (2009) 0.97
Quercetin-induced ubiquitination and down-regulation of Her-2/neu. J Cell Biochem (2008) 0.96
VEGI-192, a new isoform of TNFSF15, specifically eliminates tumor vascular endothelial cells and suppresses tumor growth. Clin Cancer Res (2005) 0.94
The endothelial cell-produced antiangiogenic cytokine vascular endothelial growth inhibitor induces dendritic cell maturation. J Immunol (2007) 0.94
TNFSF15 inhibits vasculogenesis by regulating relative levels of membrane-bound and soluble isoforms of VEGF receptor 1. Proc Natl Acad Sci U S A (2013) 0.91
VEGI-armed oncolytic adenovirus inhibits tumor neovascularization and directly induces mitochondria-mediated cancer cell apoptosis. Cell Res (2009) 0.85
Down-modulation of TNFSF15 in ovarian cancer by VEGF and MCP-1 is a pre-requisite for tumor neovascularization. Angiogenesis (2011) 0.85
Vascular endothelial growth inhibitor (VEGI; TNFSF15) inhibits bone marrow-derived endothelial progenitor cell incorporation into Lewis lung carcinoma tumors. Angiogenesis (2010) 0.84
Sensitization of endothelial cells to VEGI-induced apoptosis by inhibiting the NF-kappaB pathway. Apoptosis (2009) 0.78
The first Tianjin, China forum on tumor microenvironment. Cancer Res (2011) 0.77
Vascular endothelial growth inhibitor (VEGI), an endogenous negative regulator of angiogenesis. Semin Ophthalmol (2006) 0.77
Interferon-γ produced by tumor-infiltrating NK cells and CD4+ T cells downregulates TNFSF15 expression in vascular endothelial cells. Angiogenesis (2013) 0.77
Preparation of functionalized alkynyl magnetic microspheres for the selective enrichment of cell glycoproteins based on click chemistry. Biomacromolecules (2012) 0.75
Meeting report: The second Tianjin Forum on tumor microenvironment, Tianjin, China, June 22-24, 2012. Protein Cell (2012) 0.75
Recombinant GnRH-p53 protein sensitizes breast cancer cells to 5-fluorouracil-induced apoptosis in vitro and in vivo. Apoptosis (2013) 0.75
Tumor microenvironment: bidirectional interactions between cancer cells and normal cells. Protein Cell (2010) 0.75